# N2OFF Inc. (NITO)

Source: https://www.quantisnow.com/company/NITO
Generated: 2026-10-30T16:29:08.567Z

- Ticker: NITO
- Exchange: NASDAQ
- Sector: Industrials
- Industry: Agricultural Chemicals

## Latest NITO news and filings

- 2026-03-02 12:29 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by N2OFF Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-n2off-inc-6420731)
- 2026-02-26 21:17 UTC [SEC Form 8-K] [N2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities](https://www.quantisnow.com/insight/n2off-inc-filed-sec-form-8-k-unregistered-sales-of-equity-6416450)
- 2026-02-25 14:30 UTC [SEC Form 8-K] [N2OFF Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure](https://www.quantisnow.com/insight/n2off-inc-filed-sec-form-8-k-amendments-to-articles-of-6412238)
- 2026-02-25 13:30 UTC [Mergers & Acquisitions] [N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company](https://www.quantisnow.com/insight/n2off-announcing-corporate-rebranding-as-nexentis-technologies---innovative-ai-6412056)
- 2026-02-12 12:25 UTC [MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases](https://www.quantisnow.com/insight/mitocarex-bio-reports-successful-results-in-vitro-mitoline-powered-small-molecules-6388271)
- 2026-02-11 21:05 UTC [SEC Form 4] [Chief Executive Officer Palach David was granted 100,000 units of Restricted Shares of Common Stock (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-palach-david-was-granted-100000-units-of-6386555)
- 2026-02-11 21:05 UTC [SEC Form 4] [Controller Zakai Shlomo was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)](https://www.quantisnow.com/insight/controller-zakai-shlomo-was-granted-50000-units-of-restricted-shares-6386554)
- 2026-02-11 21:05 UTC [SEC Form 4] [Director Weiss Amitay was granted 116,286 units of Restricted Shares of Common Stock (SEC Form 4)](https://www.quantisnow.com/insight/director-weiss-amitay-was-granted-116286-units-of-restricted-shares-6386551)
- 2026-02-11 21:05 UTC [SEC Form 4] [Chief Financial Officer Barda Lital was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-barda-lital-was-granted-50000-units-of-6386548)
- 2026-02-02 13:05 UTC [In Spaceflight Conditions: N2OFF's MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions](https://www.quantisnow.com/insight/in-spaceflight-conditions-n2offs-mitocarex-bio-highlights-co-founders-innovative-research-6369136)
- 2026-01-22 12:32 UTC [N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform](https://www.quantisnow.com/insight/n2off-mitocarex-bio-announces-positive-in-vitro-results-from-its-6357058)
- 2026-01-15 13:32 UTC [N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions](https://www.quantisnow.com/insight/n2off-mitocarex-bio-spotlights-co-founders-pioneering-research-on-mitochondrial-carriers-6350293)
- 2026-01-13 21:05 UTC [SEC Form 8-K] [N2OFF Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/n2off-inc-filed-sec-form-8-k-entry-into-a-material-6348031)
- 2026-01-12 14:15 UTC [SEC Form 8-K] [N2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities](https://www.quantisnow.com/insight/n2off-inc-filed-sec-form-8-k-unregistered-sales-of-equity-6345986)
- 2026-01-05 14:20 UTC [N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake](https://www.quantisnow.com/insight/n2off-advances-340000-payment-to-gain-better-terms-in-flag-6333619)
- 2025-12-29 13:22 UTC [N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy](https://www.quantisnow.com/insight/n2off-accelerates-european-renewable-energy-momentum-with-major-de-risking-milestones-6327958)
- 2025-12-16 21:05 UTC [SEC Form 8-K] [N2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/n2off-inc-filed-sec-form-8-k-unregistered-sales-of-equity-6317930)
- 2025-11-18 14:12 UTC [N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination](https://www.quantisnow.com/insight/n2off-mitocarex-identifies-hit-compounds-and-targets-preclinical-candidate-nomination-6284339)
- 2025-11-13 21:32 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by N2OFF Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-n2off-inc-6277917)
- 2025-11-12 21:06 UTC [SEC Form 8-K] [Amendment: N2OFF Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-n2off-inc-filed-sec-form-8-k-other-events-financial-6274390)
- 2025-11-03 21:05 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by N2OFF Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-n2off-inc-6256462)
- 2025-10-30 13:25 UTC [N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers](https://www.quantisnow.com/insight/n2off-completed-merger-with-cancer-drug-discovery-company-targeting-tough-to-treat-6251768)
- 2025-10-28 20:05 UTC [SEC Form 3] [New insider Silberman Alon claimed ownership of 454,127 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-silberman-alon-claimed-ownership-of-454127-shares-sec-6247798)
- 2025-10-24 20:06 UTC [SEC Form SCHEDULE 13G filed by N2OFF Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-n2off-inc-6244551)
- 2025-10-24 20:05 UTC [SEC Form 3] [New insider Scisparc Ltd. claimed ownership of 490,751 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-scisparc-ltd-claimed-ownership-of-490751-shares-sec-6244533)
- 2025-10-24 13:00 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by N2OFF Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-n2off-inc-6244239)
- 2025-10-23 20:03 UTC [Public Offering] [SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer](https://www.quantisnow.com/insight/scisparc-announces-closing-of-the-sale-to-n2off-of-majority-owned-6243260)
- 2025-10-23 20:01 UTC [SEC Form 8-K] [N2OFF Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/n2off-inc-filed-sec-form-8-k-completion-of-acquisition-or-6243252)
- 2025-10-23 12:25 UTC [Public Offering] [N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer](https://www.quantisnow.com/insight/n2off-announces-closing-of-merger-with-drug-discovery-company-targeting-6242818)
- 2025-10-08 13:05 UTC [SEC Form 8-K] [N2OFF Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/n2off-inc-filed-sec-form-8-k-notice-of-delisting-or-6227336)
- 2025-10-08 13:00 UTC [N2OFF Regains Compliance with Nasdaq Minimum Bid Price Requirement](https://www.quantisnow.com/insight/n2off-regains-compliance-with-nasdaq-minimum-bid-price-requirement-6227279)
- 2025-09-29 20:03 UTC [SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer](https://www.quantisnow.com/insight/scisparc-n2off-shareholders-approve-merger-with-scisparcs-majority-owned-subsidiary-6214368)
- 2025-09-25 20:30 UTC [SEC Form 8-K] [N2OFF Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/n2off-inc-filed-sec-form-8-k-submission-of-matters-to-6212078)
- 2025-09-25 20:01 UTC [N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer](https://www.quantisnow.com/insight/n2off-stockholders-approve-merger-with-drug-discovery-company-targeting-resistant-6211830)
- 2025-09-18 13:39 UTC [SEC Form 8-K] [N2OFF Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/n2off-inc-filed-sec-form-8-k-other-events-financial-statements-6205294)
- 2025-09-18 13:00 UTC [N2OFF Announces Reverse Stock Split](https://www.quantisnow.com/insight/n2off-announces-reverse-stock-split-6205188)
- 2025-09-18 11:50 UTC [N2OFF Provides Business Update on Successful Execution of Solar and Energy Storage Initiatives Across Europe](https://www.quantisnow.com/insight/n2off-provides-business-update-on-successful-execution-of-solar-and-6204973)
- 2025-09-11 11:42 UTC [N2OFF to Expand its Melz Solar Project with Battery Storage](https://www.quantisnow.com/insight/n2off-to-expand-its-melz-solar-project-with-battery-storage-6197321)
- 2025-09-09 20:15 UTC [SEC Form 8-K] [N2OFF Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/n2off-inc-filed-sec-form-8-k-entry-into-a-material-6195101)
- 2025-08-27 18:53 UTC [SEC Form 424B3] [SEC Form 424B3 filed by N2OFF Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-n2off-inc-6180620)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NITO
- RSS and alerts for NITO: https://www.quantisnow.com/docs/rss-feeds.md